Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 19/20 | 0.82 |
| ▸ | ESR1 | P03372 | 14/20 | 0.82 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1379350 | 0.90 | ESR2 (1.00) | ESR2ESR1HDAC6 | |
| SCHEMBL2137383 | 0.79 | DHODH (0.54) | ESR2ESR1KDM4EALDH1A1HPGD | |
| SCHEMBL5436427 | 0.78 | ESR2 (0.80) | ESR2ESR1HDAC6 | |
| SCHEMBL1375183 | 0.75 | ESR2 (1.00) | ESR2ESR1HDAC6 | |
| SCHEMBL13865475 | 0.74 | ESR2 (0.82) | ESR2ESR1HDAC6 | |
| SCHEMBL29138308 | 0.74 | C1R (0.53) | ESR2ESR1KDM4EALDH1A1HPGD | |
| SCHEMBL13865474 | 0.74 | ESR1 (0.70) | ESR2ESR1KDM4EALDH1A1HPGD | |
| SCHEMBL2140306 | 0.73 | NPC1 (0.60) | HDAC6KDM4EALDH1A1HPGD | |
| SCHEMBL5417126 | 0.72 | ESR1 (0.51) | ESR2ESR1HDAC6KDM4EALDH1A1 | |
| SCHEMBL6987828 | 0.71 | ESR2 (0.64) | ESR2ESR1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531564-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531564-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080255057-A1 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255057-A1 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255057-A1 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | ESR1, CYP19A1, ESR2 | ESR2 3/4885ESR1 1/4885HDAC6 1696/4885 |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885HDAC6 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.